Mustang Bio (MBIO) Return on Capital Employed (2016 - 2026)
Mustang Bio (MBIO) posted quarterly Return on Capital Employed of 34.99% for Q1 2026, up 114049.0% year-over-year from N/an in Q1 2025, and down 51.97% quarter-over-quarter from 23.02% in Q4 2025.
Mustang Bio (MBIO) Return on Capital Employed (2016 - 2026) Analysis & Trends
Mustang Bio (MBIO) has reported Return on Capital Employed for 11 consecutive years, with 34.99% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 114049.0% year-over-year to 34.99%; the TTM figure through Mar 2026 stood at 34.99% (up 114049.0% YoY), while the FY2025 annual figure was 43.93%, up 172954.0% from the prior year.
- Return on Capital Employed declined to 34.99% in Q1 2026 per MBIO's latest filing, from 23.02% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 3003.15% in Q1 2024 and bottomed at 1301.97% in Q4 2023.
- Historically, Return on Capital Employed has averaged 38.97% across 5 years, with a median of 63.38% in 2022.
- Annual changes were most pronounced in 2024 — Return on Capital Employed surged 310669 bps — and 2025, when it tumbled 417863 bps.
- Mustang Bio's Return on Capital Employed stood at 89.05% in 2022, then slumped by 1362 bps to 1301.97% in 2023, then surged by 129 bps to 372.72% in 2024, then plunged by 106 bps to 23.02% in 2025, then sank by 52 bps to 34.99% in 2026.
- Business Quant data shows MBIO's Return on Capital Employed at 34.99% in Q1 2026, 23.02% in Q4 2025, and 41.09% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | 7.88% |
| 10 | Mustang Bio | 3.86 Mn | 3.86 Mn | - | -43.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.06% |
| Mar 31, 2026 | -34.99% |
| Dec 31, 2025 | -23.02% |
| Sep 30, 2025 | -41.09% |
| Jun 30, 2025 | -90.90% |
| Mar 31, 2025 | -1,175.48% |
| Dec 31, 2024 | 372.72% |
| Sep 30, 2024 | 333.74% |
| Jun 30, 2024 | 751.44% |
| Mar 31, 2024 | 3,003.15% |
| Dec 31, 2023 | -1,301.97% |
| Sep 30, 2023 | -562.37% |
| Jun 30, 2023 | -177.98% |
| Mar 31, 2023 | -103.55% |
| Dec 31, 2022 | -89.05% |
| Sep 30, 2022 | -75.48% |
| Jun 30, 2022 | -63.38% |
| Mar 31, 2022 | -59.26% |
| Dec 31, 2021 | -56.01% |
| Sep 30, 2021 | -52.41% |